基本信息
浏览量:4
职业迁徙
个人简介
Dr Mitsiades’ research focuses on developing novel therapies which neutralize the ability of tumor cells from multiple myeloma (MM), other blood cancers or metastatic solid tumors to develop resistance to pharmacological and immune therapies. Toward this goal, Dr Mitsiades and his lab have been developing preclinical models to simulate more accurately the biological behavior and treatment response vs. resistance of tumor cells as they interact with nonmalignant cells of their local tissues. Dr. Mitsiades’ work documented that nonmalignant "accessory" cells of the tumor microenvironment (e.g bone marrow stromal cells) can decrease the sensitivity of MM and solid tumors to diverse drug classes and immune effector cells. His lab also defined distinct mechanisms regulating the treatment response vs. resistance of solid tumor cells within their 3-dimensional architecture and how tumor cells can develop reversible persistence to diverse types of chemotherapeutics. With these models and CRISPR-based functional genomic studies, Dr Mitsiades’ studies have been defining the mechanisms through which MM or other tumors develop resistance to established/investigational drugs or immunotherapies, determining the molecular "drivers" of MM cells, particularly those with treatment resistance, and designing rational combinations of established or novel therapies to overcome, delay or prevent treatment resistance. The preclinical studies of Dr. Mitsiades have informed the design of several regimens which are now FDA-approved, represent a standard-of-care for MM treatment or demonstrated promising activity in clinical trials. Several of these regimens contributed to the increased overall survival of MM patients in the last decade and are a "backbone" for combination with other novel agents, such as monoclonal antibodies. Dr Mitsiades' studies established that inhibition of BET bromodomain proteins, such as BRD4, suppress the function and expression of the oncoprotein c-Myc, leading to major interest for BET bromodomain inhibition in MM and other cancers.
研究兴趣
论文共 17 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023): S244-S244
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn